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Methods that allow high throughput identification of cellular targets of bioactive small molecules are 
invaluable assets in pharmaceutical research. They are useful in mechanism of action studies of leads 
identified via phenotypic screening. Alternatively, they may uncover ‘off-target’ proteins of 
established drugs, that may contribute to their therapeutic efficacy or unwanted side effects. Finally, 
such methods also allow to identify potential novel therapeutic applications of existing drugs. 
 
MAmmalian Small molecule-Protein Interaction Trap (MASPIT) is a three-hybrid approach that 
enables swift proteome-wide screening for intracellular targets of small molecules based on the JAK-
STAT signaling pathway of the cytokine receptor (CR).1,2 MASPIT employs eDHFR, fused to the CR to 
present a methotrexate (MTX) fusion compound (MFC) to the intracellular environment. This allows 
the screening of a small molecule bait against a collection of chimeric prey proteins. As a result of the 
interaction between the bait and a prey protein, the JAK-STAT pathway is activated, resulting in the 
expression of the luciferase reporter gene (cf. Fig.). 
 
A conditio sine qua non for successful MASPIT analysis is the availability of appropriate synthetic 
probes.3 In this presentation we will discuss our efforts in optimizing the MASPIT system’s selectivity 
and sensitivity based on chemical dimerizers comprising tamoxifen (TAM) as model bait. To 
circumvent cellular toxicity associated with the known MTX anchor, we explored trimethoprim (TMP) 
as an alternative prokaryote-specific eDHFR ligand. Furthermore, in an effort to stabilize the ternary 
complex, the fusion compound was selectively and covalently immobilized to the CR using a SNAP-
tag-based system (cf. Fig.).4  
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